Mesulergine | CAS#64795-35-3

MedKoo Cat#: 534888 | Name: Mesulergine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Mesulergine is metabolized into dopaminergic agonists.

Chemical Structure

Mesulergine

CAS#64795-35-3

Theoretical Analysis

MedKoo Cat#: 534888

Name: Mesulergine

CAS#: 64795-35-3

Chemical Formula: C18H26N4O2S

Exact Mass: 362.1776

Molecular Weight: 362.49

Elemental Analysis: C, 59.64; H, 7.23; N, 15.46; O, 8.83; S, 8.84

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Mesulergine

IUPAC/Chemical Name

N'-(1,6-Dimethylergolin-8alpha-yl)-N,N-dimethylsulfamide

InChi Key

JLVHTNZNKOSCNB-YSVLISHTSA-N

InChi Code

InChI=1S/C18H26N4O2S/c1-20(2)25(23,24)19-13-9-15-14-6-5-7-16-18(14)12(10-21(16)3)8-17(15)22(4)11-13/h5-7,10,13,15,17,19H,8-9,11H2,1-4H3/t13-,15+,17+/m0/s1

SMILES Code

O=S(N[C@@H](C[C@@]12[H])CN(C)[C@]1([H])CC3=CN(C)C4=C3C2=CC=C4)(N(C)C)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 362.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Antonatos S, Galanopoulou P. Effects of mu-CPP and mesulergine on dietary choices in deprived rats: possible mechanisms of their action. Prog Neuropsychopharmacol Biol Psychiatry. 2006 Jan;30(1):112-9. doi: 10.1016/j.pnpbp.2005.08.018. Epub 2005 Oct 20. PMID: 16242827. 2: Palacios JM, Pazos A, Hoyer D. A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment. Psychopharmacology (Berl). 2017 May;234(9-10):1395-1418. doi: 10.1007/s00213-017-4545-5. Epub 2017 Mar 7. PMID: 28265714. 3: Shireen E, Haleem DJ. Reversal of haloperidol-induced motor deficits by mianserin and mesulergine in rats. Pak J Pharm Sci. 2011 Jan;24(1):7-12. PMID: 21190911. 4: Palacios JM. Serotonin receptors in brain revisited. Brain Res. 2016 Aug 15;1645:46-9. doi: 10.1016/j.brainres.2015.12.042. Epub 2015 Dec 29. PMID: 26740406. 5: Baas H, Schneider E, Fischer PA, Japp G. Mesulergine and bromocriptine in long-term treatment of advanced parkinsonism. J Neural Transm. 1985;64(1):45-54. doi: 10.1007/BF01259344. PMID: 4067602. 6: López-Giménez JF, Mengod G, Palacios JM, Vilaró MT. Regional distribution and cellular localization of 5-HT2C receptor mRNA in monkey brain: comparison with [3H]mesulergine binding sites and choline acetyltransferase mRNA. Synapse. 2001 Oct;42(1):12-26. doi: 10.1002/syn.1095. PMID: 11668587. 7: Khaliq S, Haider S, Saleem S, Memon Z, Haleem DJ. Influence of serotonergic 5-HT2C receptor antagonist mesulergine in the reversal of memory deficits induced by mCPP. J Coll Physicians Surg Pak. 2012 Feb;22(2):75-9. PMID: 22313641. 8: Hemedah M, Coupar IM, Mitchelson FJ. [3H]-Mesulergine labels 5-HT7 sites in rat brain and guinea-pig ileum but not rat jejunum. Br J Pharmacol. 1999 Jan;126(1):179-88. doi: 10.1038/sj.bjp.0702293. PMID: 10051134; PMCID: PMC1565797. 9: Giannakopoulos G, Galanopoulou P, Daifotis Z, Couvaris C. Effects of mesulergine treatment on diet selection, brain serotonin (5-HT) and dopamine (DA) turnover in free feeding rats. Prog Neuropsychopharmacol Biol Psychiatry. 1998 Jul;22(5):803-13. doi: 10.1016/s0278-5846(98)00041-4. PMID: 9723121. 10: Schneider E, Baas H, Fischer PA, Japp G. Three-year observation of mesulergine (CU 32-085) in advanced and newly treated parkinsonism. J Neurol. 1985;232(1):24-8. doi: 10.1007/BF00314036. PMID: 3998771. 11: Dupont E, Mikkelsen B, Jakobsen J. Mesulergine in early Parkinson's disease: a double blind controlled trial. J Neurol Neurosurg Psychiatry. 1986 Apr;49(4):390-5. doi: 10.1136/jnnp.49.4.390. PMID: 3517235; PMCID: PMC1028763. 12: Marazziti D, Rossi A, Giannaccini G, Zavaglia KM, Dell'Osso L, Lucacchini A, Cassano GB. Distribution and characterization of [3H]mesulergine binding in human brain postmortem. Eur Neuropsychopharmacol. 1999 Dec;10(1):21-6. doi: 10.1016/s0924-977x(99)00045-0. PMID: 10647092. 13: Pfeiffer RF. The pharmacology of mesulergine. Clin Neuropharmacol. 1985;8(1):64-72. doi: 10.1097/00002826-198503000-00006. PMID: 3884151. 14: Grossman A, Bouloux PM, Loneragan R, Rees LH, Wass JA, Besser GM. Comparison of the clinical activity of mesulergine and pergolide in the treatment of hyperprolactinaemia. Clin Endocrinol (Oxf). 1985 May;22(5):611-6. doi: 10.1111/j.1365-2265.1985.tb02996.x. PMID: 4028459. 15: Pisarek H, Stepien H, Pawlikowski M. Effect of mesulergine on prolactin secretion and dopamine D2 receptors-adaptive changes in diethylstilbestrol- induced hyperplasia of the rat anterior pituitary. Endocr Regul. 1992 Mar;26(1):17-22. PMID: 1421203. 16: Martín-Cora FJ, Pazos A. Autoradiographic distribution of 5-HT7 receptors in the human brain using [3H]mesulergine: comparison to other mammalian species. Br J Pharmacol. 2004 Jan;141(1):92-104. doi: 10.1038/sj.bjp.0705576. Epub 2003 Dec 1. PMID: 14656806; PMCID: PMC1574165. 17: Borges JL, Schran HF, Evans WS, Rogol AD, Kaiser DL, MacLeod RM, Boyett RL, Elton RL, Thorner MO. Mesulergine, a new dopamine agonist: effects on anterior pituitary function and kinetics. Clin Pharmacol Ther. 1984 Nov;36(5):696-703. doi: 10.1038/clpt.1984.242. PMID: 6386276. 18: Wang Y, Gu Q, Cynader MS. Blockade of serotonin-2C receptors by mesulergine reduces ocular dominance plasticity in kitten visual cortex. Exp Brain Res. 1997 Apr;114(2):321-8. doi: 10.1007/pl00005640. PMID: 9166921. 19: Begaud B, Dang Tran L, Montastruc JL, Montastruc P. Antihypertensive effects of mesulergine: further evidence for a peripheral site of action of dopamine agonists. Fundam Clin Pharmacol. 1987;1(3):153-9. doi: 10.1111/j.1472-8206.1987.tb00554.x. PMID: 3428838. 20: Pisarek H, Stepien H. The effect of mesulergine on prolactin secretion and anterior pituitary cells morphology in diethylstilboestrol-treated female Wistar rats. Histol Histopathol. 1992 Jan;7(1):111-7. PMID: 1576426.